COMMUNIQUÉS West-GlobeNewswire

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany
09/05/2018
SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD), Parkinson's (PD) and other [...]
Proteon Therapeutics Announces First Quarter 2018 Financial Results
09/05/2018
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO ), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular [...]
Endocyte Provides First Quarter 2018 Financial Results and Operational Update
09/05/2018
-Recently Updated Phase 2 Data on 177 Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress- -Positive End of Phase 2 FDA Meeting Set Stage for Successful Financing [...]
Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617
09/05/2018
-Publication includes analysis of original 30 patients previously presented at 2017 ESMO by Professor Michael Hofman of Peter MacCallum Cancer Centre- -Relative to previously presented data, publication reflects longer [...]
BioSig Technologies Announces Acceptance of Paper for the 40th International Conference of the IEEE Engineering in Medicine and Biology Society
09/05/2018
Paper regarding unipolar intracardiac signals as a parameter for catheter contact to be presented at EMBC ‘18 July 17-21 in Honolulu, Hawaii Santa Monica, CA, May 09, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( [...]
Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018
09/05/2018
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a [...]
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018
09/05/2018
HOUSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH ), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
09/05/2018
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today [...]
Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
09/05/2018
Lead product candidate, KB103, shown to successfully transfer COL7A1 gene and to correct recessive dystrophic epidermolysis bullosa (RDEB) PITTSBURGH, May 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal [...]
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update
09/05/2018
3-month Phase 2 data presented at PANLAR 2018 indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared [...]
CareDx expands NGS Transplant Product Offerings
09/05/2018
License and Commercialization Agreement with Illumina BRISBANE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- CareDx (NASDAQ: CDNA ), today announced that, as reported in its Current Report on Form 8-K filed with the [...]
Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update
09/05/2018
CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE ), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases [...]
Nephros Reports First Quarter 2018 Financial Results
09/05/2018
Quarterly Product Revenue Up 39% Year-over-Year; Reiterates Full Year 2018 Revenue Guidance of $6 Million SOUTH ORANGE, N.J., May 09, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage [...]
Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
09/05/2018
CRANBURY, N.J., May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America [...]
Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
09/05/2018
Pre-Commercial Launch Preparations Underway for AZEDRA ® (iobenguane I 131) ahead of U.S. Food and Drug Administration (FDA) July 30 th Action Date Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging [...]
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
09/05/2018
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO - - Guidance confirmed, funded through to early 2020 - - [...]
Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
09/05/2018
-- New drug applications for omadacycline accepted for priority review by FDA; PDUFA action date in October 2018 -- -- Company on track for a first quarter 2019 omadacycline U.S. launch -- -- Company strengthens balance [...]
Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)
09/05/2018
New preclinical data provide further evidence of TAK-935/OV935’s novel mechanism of action, as a potential treatment for rare developmental and epileptic encephaolopathies (dEE) First presentation of preclinical data on [...]
ProQR Announces Results for the First Quarter of 2018
09/05/2018
Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected [...]

Pages